Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Purple Biotech (PPBT) Income from Continuing Operations (2016 - 2025)

Purple Biotech has reported Income from Continuing Operations over the past 6 years, most recently at 8057000.0 for Q4 2022.

  • Quarterly Income from Continuing Operations fell 274.62% to 8057000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was 7444000.0 through Dec 2022, down 57.22% year-over-year, with the annual reading at 26900000.0 for FY2025, 136.17% up from the prior year.
  • Income from Continuing Operations was 8057000.0 for Q4 2022 at Purple Biotech, down from 4817000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 8056000.0 in Q4 2020 and troughed at 8057000.0 in Q4 2022.
  • The 5-year median for Income from Continuing Operations is 3450000.0 (2022), against an average of 3594090.91.
  • Year-over-year, Income from Continuing Operations skyrocketed 134.05% in 2020 and then crashed 274.62% in 2022.
  • A 5-year view of Income from Continuing Operations shows it stood at 3191000.0 in 2018, then rose by 7.87% to 3442000.0 in 2019, then skyrocketed by 134.05% to 8056000.0 in 2020, then plummeted by 42.73% to 4614000.0 in 2021, then crashed by 274.62% to 8057000.0 in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Income from Continuing Operations are 8057000.0 (Q4 2022), 4817000.0 (Q3 2022), and 3450000.0 (Q2 2022).